Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor
cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of
tumor cells by blocking the enzymes necessary for their growth. Giving docetaxel with
imatinib mesylate may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel when
given together with imatinib mesylate in treating patients with locally advanced or
metastatic breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins